We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

19 hedge funds and large institutions have $883K invested in CASI Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 19 → 19 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.79% less ownership

Funds ownership: 3.38% → 2.59% (-0.79%)

22% less capital invested

Capital invested by funds: $1.12M → $883K (-$242K)

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

Holders
19
Holders Change
–
Holders Change %
0%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
7
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$6.39K
2
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$777
3
TRCT
Tower Research Capital (TRC)
New York
+$291
4
KA
Kozak & Associates
Colorado
+$24
5
Wells Fargo
Wells Fargo
California
+$2

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$116K
2
WSCM
Wellington Shields Capital Management
New York
-$59.2K
3
WSC
Wellington Shields & Co
New York
-$28.5K
4
Northern Trust
Northern Trust
Illinois
-$25.8K
5
Jane Street
Jane Street
New York
-$14.3K

CASI Hedge Fund Activity: Q3 2023 in Review

19 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2023, worth a combined $883K — down 22% from $1.12M a quarter earlier.

Fund positioning in CASI was balanced in Q3 2023: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 7 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $6.39K. The largest seller was Vanguard Group, cutting an estimated $116K.

  • 19 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $883K of CASI Pharmaceuticals stock for Q3 2023, down 22% quarter-over-quarter.
  • 2 funds opened new CASI Pharmaceuticals positions in Q3 2023 and 2 closed out, a net change of 0 holders.
  • The largest CASI Pharmaceuticals buyer in Q3 2023 was Renaissance Technologies, an estimated $6.39K added.
  • The largest CASI Pharmaceuticals seller in Q3 2023 was Vanguard Group, an estimated $116K sold.

Based on aggregated 13F filings for Q3 2023.